MTOR and cancer: The pathway activity analysis revealed a notable contribution of ECM-SRGs to cancer-related pathways, encompassing the cell cycle, apoptosis, PI3K/AKT, RAS/MAPK, RTK, and TSC/mTOR signaling pathways, EMT, hormone AR, and ER, as well as the response to DNA damage (Fig. 11A).